Genmedicn closes Series A extension for gene therapy push

What's the deal? Genmedicn BiopharmaDealroom has a profile for this one. Try Dealroom → has closed a Series A extension round, the Chinese gene therapy developer announced in October 2026. The round was led by Huade Kechuang, with participation from Botong CapitalDealroom has a profile for this one. Try Dealroom →, returning investors Enran Venture CapitalDealroom has a profile for this one. Try Dealroom →, Longmen CapitalDealroom has a profile for this one. Try Dealroom →, and Kangyuan Huiying.

What's the endgame? Genmedicn develops gene therapy drugs, focusing on classic viral vector-mediated gene therapy. It has built a pipeline of projects targeting multiple single-gene inherited diseases.

Why now? The fresh capital is set to speed up development of the company's hematopoietic stem cell gene therapy drugs, a technically demanding area that treats inherited blood disorders by modifying a patient's own stem cells.

The signal: Returning backers joining a new lead investor points to continued confidence in China's gene therapy sector, where developers are racing to turn single-gene disease research into approved treatments.

Read more: itjuzi.com

Image credit: National Institutes of Health (NIH)